ER reactivation therapy for breast cancer (POLLY)
This multi-center investigator-initiated Phase II study will assess the therapeutic benefit of alternating 17b-estradiol/aromatase inhibitor therapies on a 2-month/4-month schedule for prevention of disease progression.

Phase II study of Neoadjuvant ArOMatase Inhibitor therapy for ER+ breast cancer (NAOMI)
This study will identify changes in tumor metabolic markers in post-menopausal patients with ER+/HER2- breast cancer treated with neoadjuvant letrozole, and identify factors predictive of patient adherence to adjuvant endocrine therapy.

CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth (CATRINA)
This study will determine how Molecular Tumor Board evaluation impacts treatment decisions.

Tumor-specific plasma DNA
This study explores the potential of using tumor-derived DNA in the bloodstream as a quantitative biomarker of tumor burden and response to chemotherapy in women with triple-negative or HER2+ breast cancer, or patients with lung cancer.